Hyperprogressive disease in leiomyosarcoma: A threat to the use of single-agent anti-PD-(L)1 therapy?

Tarek Assi; Olivier Mir

doi:10.2217/imt-2021-0297

Hyperprogressive disease in leiomyosarcoma: A threat to the use of single-agent anti-PD-(L)1 therapy?

Tarek Assi, Olivier Mir

Research output: Contribution to journal › Review article › peer-review

2 Citations (Scopus)

Original language	English
Pages (from-to)	271-274
Number of pages	4
Journal	Immunotherapy
Volume	14
Issue number	5
DOIs	https://doi.org/10.2217/imt-2021-0297
Publication status	Published - 1 Apr 2022

Keywords

checkpoint inhibitors
hyperprogression
immunotherapy
leiomyosarcoma
sarcoma
soft tissue

Access to Document

10.2217/imt-2021-0297

Cite this

@article{ba4c2c792ccb4321af7bdbee1801e627,

title = "Hyperprogressive disease in leiomyosarcoma: A threat to the use of single-agent anti-PD-(L)1 therapy?",

keywords = "checkpoint inhibitors, hyperprogression, immunotherapy, leiomyosarcoma, sarcoma, soft tissue",

author = "Tarek Assi and Olivier Mir",

year = "2022",

month = apr,

day = "1",

doi = "10.2217/imt-2021-0297",

language = "English",

volume = "14",

pages = "271--274",

journal = "Immunotherapy",

issn = "1750-743X",

number = "5",

}

TY - JOUR

T1 - Hyperprogressive disease in leiomyosarcoma

T2 - A threat to the use of single-agent anti-PD-(L)1 therapy?

AU - Assi, Tarek

AU - Mir, Olivier

PY - 2022/4/1

Y1 - 2022/4/1

KW - checkpoint inhibitors

KW - hyperprogression

KW - immunotherapy

KW - leiomyosarcoma

KW - sarcoma

KW - soft tissue

UR - http://www.scopus.com/inward/record.url?scp=85126152505&partnerID=8YFLogxK

U2 - 10.2217/imt-2021-0297

DO - 10.2217/imt-2021-0297

M3 - Review article

C2 - 35187949

AN - SCOPUS:85126152505

SN - 1750-743X

VL - 14

SP - 271

EP - 274

JO - Immunotherapy

JF - Immunotherapy

IS - 5

ER -

Hyperprogressive disease in leiomyosarcoma: A threat to the use of single-agent anti-PD-(L)1 therapy?

Keywords

Access to Document

Other files and links

Cite this